Name | Number of supported studies | Average coverage | |
---|---|---|---|
fibroblast | 10 studies | 33% ± 16% | |
mesothelial cell | 9 studies | 58% ± 33% | |
transit amplifying cell | 5 studies | 45% ± 22% | |
goblet cell | 4 studies | 30% ± 10% | |
intestinal crypt stem cell | 4 studies | 29% ± 9% | |
paneth cell | 4 studies | 85% ± 21% | |
adventitial cell | 4 studies | 52% ± 16% | |
epithelial cell | 4 studies | 32% ± 12% | |
luminal cell of prostate epithelium | 4 studies | 42% ± 6% | |
progenitor cell | 3 studies | 41% ± 20% |
Insufficient scRNA-seq data for expression of PLA2G2A at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 73% | 13694.46 | 178 / 245 | 97% | 3092.55 | 486 / 502 |
intestine | 76% | 16087.41 | 735 / 966 | 68% | 472.71 | 358 / 527 |
bladder | 81% | 24218.10 | 17 / 21 | 44% | 260.76 | 220 / 504 |
liver | 66% | 35376.18 | 150 / 226 | 46% | 682.43 | 187 / 406 |
ureter | 0% | 0 | 0 / 0 | 100% | 497.72 | 1 / 1 |
esophagus | 61% | 10618.87 | 887 / 1445 | 34% | 218.35 | 62 / 183 |
adipose | 93% | 27703.93 | 1125 / 1204 | 0% | 0 | 0 / 0 |
stomach | 30% | 3857.71 | 107 / 359 | 63% | 822.49 | 181 / 286 |
blood vessel | 76% | 18559.31 | 1019 / 1335 | 0% | 0 | 0 / 0 |
ovary | 69% | 13857.16 | 124 / 180 | 6% | 8.67 | 25 / 430 |
breast | 56% | 8135.38 | 258 / 459 | 14% | 35.50 | 158 / 1118 |
heart | 70% | 31537.95 | 601 / 861 | 0% | 0 | 0 / 0 |
thymus | 44% | 4548.92 | 289 / 653 | 7% | 8.74 | 43 / 605 |
skin | 29% | 2581.03 | 530 / 1809 | 13% | 14.64 | 63 / 472 |
lung | 25% | 3218.62 | 146 / 578 | 13% | 99.73 | 155 / 1155 |
pancreas | 2% | 132.17 | 8 / 328 | 31% | 183.06 | 55 / 178 |
uterus | 9% | 1013.71 | 15 / 170 | 10% | 36.78 | 46 / 459 |
muscle | 19% | 1358.35 | 150 / 803 | 0% | 0 | 0 / 0 |
brain | 0% | 0 | 0 / 2642 | 10% | 35.05 | 73 / 705 |
tonsil | 0% | 0 | 0 / 0 | 7% | 6.27 | 3 / 45 |
kidney | 3% | 257.24 | 3 / 89 | 2% | 1.95 | 15 / 901 |
lymph node | 0% | 0 | 0 / 0 | 3% | 2.52 | 1 / 29 |
adrenal gland | 2% | 55.61 | 5 / 258 | 1% | 5.15 | 2 / 230 |
peripheral blood | 2% | 211.03 | 16 / 929 | 0% | 0 | 0 / 0 |
spleen | 0% | 31.41 | 1 / 241 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0010744 | Biological process | positive regulation of macrophage derived foam cell differentiation |
GO_0036335 | Biological process | intestinal stem cell homeostasis |
GO_0006954 | Biological process | inflammatory response |
GO_0016042 | Biological process | lipid catabolic process |
GO_0031640 | Biological process | killing of cells of another organism |
GO_0034374 | Biological process | low-density lipoprotein particle remodeling |
GO_0050830 | Biological process | defense response to Gram-positive bacterium |
GO_0042130 | Biological process | negative regulation of T cell proliferation |
GO_0046470 | Biological process | phosphatidylcholine metabolic process |
GO_0046473 | Biological process | phosphatidic acid metabolic process |
GO_0006644 | Biological process | phospholipid metabolic process |
GO_0050729 | Biological process | positive regulation of inflammatory response |
GO_0046337 | Biological process | phosphatidylethanolamine metabolic process |
GO_0070374 | Biological process | positive regulation of ERK1 and ERK2 cascade |
GO_1902563 | Biological process | regulation of neutrophil activation |
GO_0050482 | Biological process | arachidonic acid secretion |
GO_0005615 | Cellular component | extracellular space |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0048471 | Cellular component | perinuclear region of cytoplasm |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0005741 | Cellular component | mitochondrial outer membrane |
GO_0030141 | Cellular component | secretory granule |
GO_0047498 | Molecular function | calcium-dependent phospholipase A2 activity |
GO_0005543 | Molecular function | phospholipid binding |
GO_0004623 | Molecular function | phospholipase A2 activity |
GO_0005509 | Molecular function | calcium ion binding |
Gene name | PLA2G2A |
Protein name | Phospholipase A2 (EC 3.1.1.4) Phospholipase A2, membrane associated (EC 3.1.1.4) (GIIC sPLA2) (Group IIA phospholipase A2) (Non-pancreatic secretory phospholipase A2) (NPS-PLA2) (Phosphatidylcholine 2-acylhydrolase 2A) Phospholipase A2, membrane associated (EC 3.1.1.4) (GIIC sPLA2) (Group IIA phospholipase A2) (Phosphatidylcholine 2-acylhydrolase 2A) |
Synonyms | PLA2L RASF-A PLA2B |
Description | FUNCTION: Secretory calcium-dependent phospholipase A2 that primarily targets extracellular phospholipids with implications in host antimicrobial defense, inflammatory response and tissue regeneration . Hydrolyzes the ester bond of the fatty acyl group attached at sn-2 position of phospholipids (phospholipase A2 activity) with preference for phosphatidylethanolamines and phosphatidylglycerols over phosphatidylcholines . Contributes to lipid remodeling of cellular membranes and generation of lipid mediators involved in pathogen clearance. Displays bactericidal activity against Gram-positive bacteria by directly hydrolyzing phospholipids of the bacterial membrane . Upon sterile inflammation, targets membrane phospholipids of extracellular mitochondria released from activated platelets, generating free unsaturated fatty acids such as arachidonate that is used by neighboring leukocytes to synthesize inflammatory eicosanoids such as leukotrienes. Simultaneously, by compromising mitochondrial membrane integrity, promotes the release in circulation of potent damage-associated molecular pattern molecules that activate the innate immune response . Plays a stem cell regulator role in the intestinal crypt. Within intracellular compartment mediates Paneth cell differentiation and its stem cell supporting functions by inhibiting Wnt signaling pathway in intestinal stem cell (ICS). Secreted in the intestinal lumen upon inflammation, acts in an autocrine way and promotes prostaglandin E2 synthesis that stimulates Wnt signaling pathway in ICS cells and tissue regeneration (By similarity). May play a role in the biosynthesis of N-acyl ethanolamines that regulate energy metabolism and inflammation. Hydrolyzes N-acyl phosphatidylethanolamines to N-acyl lysophosphatidylethanolamines, which are further cleaved by a lysophospholipase D to release N-acyl ethanolamines . Independent of its catalytic activity, acts as a ligand for integrins . Binds to and activates integrins ITGAV:ITGB3, ITGA4:ITGB1 and ITGA5:ITGB1 . Binds to a site (site 2) which is distinct from the classical ligand-binding site (site 1) and induces integrin conformational changes and enhanced ligand binding to site 1 . Induces cell proliferation in an integrin-dependent manner . . |
Accessions | Q8NI47 ENST00000375111.7 ENST00000400520.8 P14555 A0A3B3IRX2 ENST00000482011.3 ENST00000649436.1 |